Serum HE4 and diagnosis of ovarian cancer in postmenopausal women with adnexal masses.

ABSTRACT:

Background

Transvaginal ultrasound and serum CA125 are routinely used for differential diagnosis of pelvic adnexal mass. Use of human epididymis 4 was approved in the United States in 2011. However, there is scarcity of studies evaluating the additional value of human epididymis 4.

Objective

The objective of the study was to evaluate the performance characteristics of transvaginal ultrasound, CA125, and human epididymis 4 for differential diagnosis of ovarian cancer in postmenopausal women with adnexal masses.

Study design

This was a cohort study nested within the screen arms of the multicenter randomized controlled trial, United Kingdom Collaborative Trial of Ovarian Cancer Screening, based in England, Wales, and Northern Ireland. In United Kingdom Collaborative Tria

SUBMITTER: Gentry-Maharaj A 

PROVIDER: S-EPMC7471839 | biostudies-literature | 2020 Jan

REPOSITORIES: biostudies-literature